Moderna (NASDAQ:MRNA) Earns Market Perform Rating from William Blair
William Blair has reaffirmed a "market perform" rating for Moderna (NASDAQ:MRNA) shares. The stock has faced mixed ratings from various analysts, with Bank of America lowering its target price to $34 and setting an "underperform" rating. Other firms have also adjusted their ratings and target prices. Currently, Moderna's consensus rating is "Hold" with a target price of $58.70. The stock traded down 1.1% to $24.90, with significant institutional ownership at 75.33%.
Moderna (NASDAQ:MRNA - Get Free Report)'s stock had its "market perform" rating restated by research analysts at William Blair in a research note issued to investors on Thursday,RTT News reports.
- MarketBeat Week in Review – 03/10 - 03/14
MRNA has been the subject of several other reports. Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Argus downgraded Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Finally, Leerink Partners dropped their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $58.70.
Get Our Latest Stock Analysis on Moderna
Moderna Stock Down 1.1 %
- Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Shares of MRNA traded down $0.29 during trading hours on Thursday, hitting $24.90. 1,485,493 shares of the company were exchanged, compared to its average volume of 7,207,112. The company has a market cap of $9.63 billion, a price-to-earnings ratio of -2.69 and a beta of 2.23. The firm's fifty day moving average is $31.10 and its 200 day moving average is $40.37. Moderna has a fifty-two week low of $23.15 and a fifty-two week high of $170.47.
Institutional Investors Weigh In On Moderna
Institutional investors have recently modified their holdings of the company. Allworth Financial LP grew its holdings in Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after acquiring an additional 281 shares during the period. Howard Capital Management Inc. grew its stake in Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after purchasing an additional 297 shares during the period. Itau Unibanco Holding S.A. increased its holdings in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after buying an additional 345 shares during the period. Finally, Larson Financial Group LLC boosted its holdings in shares of Moderna by 39.1% during the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after buying an additional 356 shares in the last quarter. 75.33% of the stock is owned by institutional investors.
Moderna Company Profile
(Get Free Report)- Moderna: A Generational Opportunity for Investors in 2025
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
- Five stocks we like better than Moderna
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
- Using the MarketBeat Stock Split Calculator
- Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar
- Stock Analyst Ratings and Canadian Analyst Ratings
- Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Moderna Right Now?
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
